Evidence map›Paper›PMID 37577437›Full record

ArticleFrontiers in microbiology2023

One year of SARS-CoV-2 circulation in the Nouvelle-Aquitaine region, February 2021-2022, France.

Luc Deroche, Pantxika Bellecave, Romain David, Eric Ouattara, Magali Garcia, France Roblot, Laurence Boinot, Jean-François Faucher, Aurélie Rejasse, Guillaume Gschwind and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Luc DerocheVirology Laboratory, CHU Poitiers, Poitiers, France.
Pantxika BellecaveVirology Laboratory, CHU Bordeaux, Bordeaux, France.
Romain DavidVirology Laboratory, CHU Bordeaux, Bordeaux, France.
Eric OuattaraMedical Information Analysis and Coordination Unit (UCAIM-DIM), Medical Information Department, Bordeaux University Hospital, Bordeaux, France.
Magali GarciaVirology Laboratory, CHU Poitiers, Poitiers, France.
France RoblotTropical Infectious Diseases Department, Poitiers University Hospital, Poitiers, France.
Laurence BoinotService d'Information Médicale, CHU Poitiers, Poitiers, France.
Jean-François FaucherTropical Infectious Diseases Department, Limoges University Hospital, Limoges, France.
Aurélie RejasseMedical Information Department, Limoges University Hospital, Limoges, France.
Guillaume GschwindMedical Information Department, Limoges University Hospital, Limoges, France.
Denis MalvyDepartment of Infectious and Tropical Diseases, CHU Bordeaux, Bordeaux, France.
Laurent FilleulRegional Office-Nouvelle Aquitaine, Santé publique France, Bordeaux, France.
Sylvie RogezVirology Laboratory, CHU Limoges, Limoges, France.
Nicolas LévêqueVirology Laboratory, CHU Poitiers, Poitiers, France.
Marie-Edith LafonVirology Laboratory, CHU Bordeaux, Bordeaux, France.
Université de Limoges · FRCentre Hospitalier Universitaire de Poitiers · FRUniversité de Poitiers · FRCentre National de la Recherche Scientifique · FRInserm · FRSanté Publique France · FRUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Since 2021, 3 variants of concern (VOC) have spread to France, causing successive epidemic waves. Objectives: To describe the features of Alpha, Delta and Omicron VOC circulation in the Nouvelle-Aquitaine region, France, between February 2021 and February 2022. Study design: Data from the three university hospitals (UH) of Nouvelle-Aquitaine were used to describe regional SARS-CoV-2 circulation (RT-PCR positive rates and identified VOC) as well as its consequences (total number of hospitalizations and admissions in intensive care unit). They were analyzed according to the predominant variant and compared with national data. Results: A total of 611,106 SARS-CoV-2 RT-PCR tests were performed in the 3 Nouvelle-Aquitaine UH during the study period. The 37,750 positive samples were analyzed by variant-specific RT-PCR or whole-genome sequencing. In 2021, Alpha VOC was detected from week 5 until week 35. Delta became the most prevalent variant (77.3%) in week 26, reaching 100% in week 35. It was replaced by Omicron, which was initially detected week 48, represented 77% of positive samples in week 52 and was still predominant in February 2022. The RT-PCR positive rates were 4.3, 4.2, and 21.9% during the Alpha, Delta and Omicron waves, respectively. The ratio between intensive care unit admissions and total hospitalizations was lower during the Omicron wave than during the two previous waves due to the Alpha and Delta variants. Conclusion: This study highlighted the need for strong regional cooperation to achieve effective SARS-CoV-2 epidemiological surveillance, in close association with the public health authorities.

Indexed as

epidemiological surveyFranceNouvelle-AquitaineSARS-CoV-2variant

Identifiers

PMID37577437
PMCPMC10420073
OpenAlexW4385335003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.